Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
Monoclonal antibodies such as lecanemab and donanemab show reduction in amyloid plaque and slowing of cognitive and functional decline (modest) in early AD (mild cognitive impairment or mild dementia).
Why it matters
Lecanemab and donanemab modestly slow cognitive and functional decline in early Alzheimer disease, while aducanumab showed mixed results and is not approved by Health Canada. Tau-targeting and anti-inflammatory agents are still under investigation and have not yet shown definitive benefit.
-
31/100
Alzheimer's disease (AD) diagnosis using MRI scans must be very accurate since the subtle differences throughout the course of the disease are difficult to identify.
Why it matters
This study used a deep learning model to classify stages of Alzheimer's disease from MRI scans, achieving 94.2% accuracy. It is a detection and staging method only and does not test any treatment, cure, or prevention.
-
For all 3 analytes, less than 10% difference was observed between the concentrations measured on day 0 and after 14 days of transportation and refrigeration.
Why it matters
This study evaluated how transportation, refrigeration and hemolysis affect measurement of amyloid-β 1-42, phosphorylated tau 181 and total tau in cerebrospinal fluid. It is about laboratory measurement quality and does not test or demonstrate any treatment, cure or prevention.
-
31/100
Alzheimer’s disease (AD) is a progressive neurodegenerative condition that affects the elderly population.
Why it matters
This study combined different types of brain scans using deep learning to detect Alzheimer's disease, reporting 98.94% accuracy. It is a detection method only and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Our findings support apathy and APOE ε4 as robust predictors of conversion to MCI and ADD, and demonstrate novel associations between antidepressant use and conversion.
Why it matters
Apathy and the APOE ε4 genotype were associated with increased risk of conversion from cognitively normal to mild cognitive impairment and from mild cognitive impairment to Alzheimer's disease dementia, and antidepressant use was also associated with conversion. These are risk associations, not a treatment or cure.
-
Alzheimer's disease (AD) is a memory and cognitive function neurodegenerative disease.
Why it matters
This study compared six pre-trained deep learning models for detecting Alzheimer's disease from MRI scans, with one model reaching 99.2% accuracy, and also created a web tool for clinicians. It is a detection method only and does not test any treatment, cure, or prevention.
-
Both diseases exhibit common genetic, epigenetic, biochemical and physiological characteristics.
Why it matters
This review argues that type 2 diabetes and Alzheimer's share many disease processes, such as insulin resistance, inflammation, and oxidative stress, and suggests joint therapies are needed. It is a review of existing knowledge and does not report a new treatment or cure.
-
Although diagnostic markers in cerebrospinal fluid (CSF) have become a rapidly growing research field, they have not as yet been investigated in relation to capacities that are of interest to geriatric psychiatry and neuropsychology, such as financial capacity.
Why it matters
This preliminary study assessed whether CSF biomarkers can predict financial capacity in patients diagnosed with major neurocognitive disorder due to Alzheimer's disease. It concerns prediction of a daily function, not treating, curing or preventing the disease.
-
Alzheimer's Disease (AD) is a global problem affecting 58 million people, expected to reach a prevalence of 88 million people by 2050.
Why it matters
This systematic review found that mHealth and virtual reality interventions improved cognition, memory, and other outcomes in older adults with Alzheimer's disease, though three interventions reported no improvements or no statistically significant improvements. It reviews technology-based cognitive interventions, not a cure or prevention for Alzheimer's disease.
-
31/100
The number of dementia cases continues to increase with Alzheimer's disease as the leading cause.
Why it matters
This paper states that the diagnostic workup of Alzheimer's dementia is complex and its clinical relevance debatable given the current lack of disease-modifying treatments. It recommends a stepwise diagnostic approach including history, physical and psychiatric examination, neuropsychological tests, routine blood tests and standard cerebral imaging.
-
Alzheimer's disease (AD) is the most common cause of dementia.
Why it matters
This review states that causal pharmacological approaches for Alzheimer's disease have not been available to date. It notes that aducanumab was recently approved in the USA but was rejected in Europe in December 2021 by the European Medicines Agency.
-
Serum TSH level is associated with cerebral Aβ burden.
Why it matters
In 69 people without overt hypothyroidism, higher-normal TSH levels were associated with greater cerebral amyloid-beta burden on PET imaging, and free thyroxine was positively associated with cognitive function. This suggests a link between thyroid hormone levels and Alzheimer's-related brain changes, but it is a cross-sectional study and does not show that treating thyroid levels prevents or cures Alzheimer's.
-
In accordance with the current German dementia guidelines, the dementia biomarkers amyloid beta 42, the tau peptides total tau and phosphorylated tau 181 are recommended for cerebrospinal fluid (CSF)-based diagnostics of dementia.
Why it matters
This review notes that the amyloid beta 42 to amyloid beta 40 ratio is superior to amyloid beta 42 alone for cerebrospinal fluid diagnosis, and that blood-based amyloid beta detection methods are currently usable in clinical studies for early diagnosis. It concerns diagnosis and does not report any treatment, cure, or prevention.
-
The existence of an effective biomarker for early detection of Alzheimer disease would facilitate improved diagnosis and stimulate therapeutic trials.
Why it matters
This paper discusses the need for biomarkers that allow earlier detection of Alzheimer's disease, since diagnosis is often delayed until later stages. It is about detection and trial screening, so it does not show a treatment, cure or prevention.
-
Genetic linkage studies suggest that Alzheimer's disease (AD) is genetically heterogeneous and that in several early onset families the disease locus is close to the amyloid precursor protein (APP) gene on chromosome 21.
Why it matters
French researchers screened 100 people with early-onset Alzheimer's, seventy-five sporadic and 25 familial, for two mutations in the amyloid precursor protein gene, APP 717 Val-->Ile and APP 713 Ala-->Val. None of the patients carried either mutation, and combined data suggested the 717 mutation accounts for less than 0.8% of early-onset cases. The authors still consider testing for it justified because of its importance for genetic counselling.
-
Anemia and iron deficiency are common in older adults, yet their relevance to blood biomarkers for Alzheimer disease (AD) remains underappreciated.
Why it matters
This review argues that anemia and iron deficiency are common conditions that can affect how Alzheimer's blood biomarkers such as p-tau217, GFAP and neurofilament light are interpreted, alongside kidney function, inflammation and body mass index. It notes that p-tau217 is closest to routine clinical use but that its interpretation depends on many patient factors, and that mechanistic work suggests plausible biological links between iron problems and brain health.
-
Alzheimer disease (AD) destroys brain cells and the patient’s memory is lost as a result of a progressive and incurable neurodegenerative disease.
Why it matters
This study proposes a deep learning method for classifying four classes of Alzheimer's disease from MRI images, reporting improved accuracy over several other methods on the ADNI-MRI dataset. It is a diagnostic classification approach and does not report any treatment, cure, or prevention.
-
Endolysosomal dysfunction has been increasingly implicated in the pathogenesis of neurodegenerative diseases.
Why it matters
This is a single case report of one 59-year-old woman with biomarker-confirmed Alzheimer disease who carried a rare CHMP2B variant, so it cannot show that this variant causes or modifies Alzheimer disease. It suggests researchers may want to study endolysosomal genes further, but no treatment, cure or prevention follows from one case.
-
12.05.2026: Debatt - En enkel blodprøve kan nå påvise fosforylert tau-protein 217 (p-tau217) – et biologisk tegn på Alzheimers sykdom, som kan være til stede mange år før de første symptomene viser seg.
Why it matters
A simple blood test can now detect phosphorylated tau protein 217 (p-tau217), a biological sign of Alzheimer's disease that may be present many years before the first symptoms. This is a diagnostic development; the text does not report any treatment, cure, or prevention.
-
Alzheimer disease (AD) is the leading cause of dementia globally and is defined by the presence of amyloid-β (Aβ) plaques and neurofibrillary tangles formed by the accumulation of phosphorylated tau (p-tau).
Why it matters
This article discusses blood-based biomarkers as a lower-cost, more accessible alternative to PET imaging and lumbar puncture for identifying biological evidence of Alzheimer's disease. It notes that variability in assay performance and uncertainty in interpreting results in the general population raise concerns about widespread clinical use.
-
Synthetic images were visually consistent, producing plausible negative and positive patterns while preserving continuity in the sagittal plane.
Why it matters
This study used a generative adversarial network to create synthetic amyloid PET images from 18F-FDG PET images, and a two-class classifier distinguished positive from negative cases with over 85% accuracy. The authors suggest amyloid images can potentially be generated from 18F-FDG PET images for clinical use, but this is an imaging method, not a treatment, cure or prevention.
-
ADRD mortality rates were slightly higher in rural areas compared to urban areas, with no significant differences between rural-adjacent and rural-nonadjacent counties in recent years.
Why it matters
This study found that Medicare claims data showed lower Alzheimer's disease and related dementias prevalence in rural areas while cognitive assessments showed higher prevalence there, suggesting underdiagnosis in claims data. It also found that states with restricted nurse practitioner practice had lower measured prevalence, and the authors suggest expanding practice authority could improve diagnosis and care, not treat or cure the disease.
-
We evaluated known AD-associated loci (Bellenguez et al. 2022) and 27 loci reached nominal significance (p < 0.05) in at least one cognitive domain.
Why it matters
This study found that some known Alzheimer risk genes affect memory, language, and executive function differently, with APOE4 showing the strongest effect on memory. It suggests that understanding these domain-specific genetic effects could guide more precise, symptom-focused interventions, though no intervention was tested.
-
From 2016 to 2022, Alzheimer’s disease mortality significantly increased among Black individuals (AAPC = 8.3%, 95% CI [2.6 to 16.0]; p < 0.05) and declined among White individuals (AAPC = −2.9%, 95% CI [−12.3 to 7.6] p < 0.05).
Why it matters
This study found that Alzheimer's disease mortality increased significantly among Black individuals and declined among White individuals in the Mississippi Delta from 2016 to 2022. It describes disparities in death rates and does not test any treatment, cure, or prevention.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Machine learning model for predicting Amyloid-β positivity and cognitive status using early-phase 18F-Florbetaben PET and clinical features
- Tau PET imaging with 18F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study
- Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease
- Early intervention in Alzheimer's disease: a health economic study of the effects of diagnostic timing
- Metabolic syndrome, mild cognitive impairment and Alzheimer's disease--the emerging role of systemic low-grade inflammation and adiposity
- Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention
- Alzheimer`s disease mortality in the United States: Cross-sectional analysis of county-level socio-environmental factors
- Combating Genetic Heterogeneity for Polygenic Prediction of Susceptibility to Brain β-Amyloid Deposition
- Clinically diagnosed Alzheimer's disease: autopsy results in 150 cases
- Age-dependent postoperative cognitive impairment and Alzheimer-related neuropathology in mice